Tactile Systems Technology, Inc. (NASDAQ:TCMD) Director Kevin H. Roche sold 14,600 shares of the company’s stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $27.49, for a total value of $401,354.00. Following the completion of the sale, the director now owns 111,784 shares of the company’s stock, valued at $3,072,942.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Tactile Systems Technology, Inc. (TCMD) traded up $0.21 on Tuesday, reaching $27.74. The company’s stock had a trading volume of 215,500 shares, compared to its average volume of 204,034. The firm has a market capitalization of $487.33, a P/E ratio of 183.53, a price-to-earnings-growth ratio of 4.51 and a beta of -0.69. Tactile Systems Technology, Inc. has a 12-month low of $14.37 and a 12-month high of $37.88.
Tactile Systems Technology (NASDAQ:TCMD) last released its earnings results on Tuesday, November 7th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.02. Tactile Systems Technology had a return on equity of 4.75% and a net margin of 5.84%. The firm had revenue of $28.28 million during the quarter, compared to the consensus estimate of $27.66 million. During the same period in the prior year, the firm posted $0.01 earnings per share. The firm’s revenue for the quarter was up 25.0% compared to the same quarter last year. analysts forecast that Tactile Systems Technology, Inc. will post 0.31 EPS for the current year.
A number of research firms have weighed in on TCMD. BTIG Research upgraded Tactile Systems Technology from a “neutral” rating to a “buy” rating in a research report on Thursday, November 9th. They noted that the move was a valuation call. Northland Securities restated a “hold” rating and issued a $31.50 target price on shares of Tactile Systems Technology in a research report on Monday, October 16th. Zacks Investment Research downgraded Tactile Systems Technology from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Sidoti began coverage on Tactile Systems Technology in a research report on Friday. They issued a “neutral” rating for the company. Finally, Guggenheim began coverage on Tactile Systems Technology in a research report on Thursday, October 12th. They issued a “buy” rating and a $47.00 target price for the company. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $34.25.
Tactile Systems Technology Company Profile
Tactile Systems Technology, Inc is a medical technology company that develops and provides medical devices for the treatment of chronic diseases at home. The Company is a manufacturer and distributor of the Flexitouch and Entre Systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition that is often an unintended consequence of cancer treatment, and the ACTitouch System, a medical device used to treat venous leg ulcers and chronic venous insufficiency.
Receive News & Ratings for Tactile Systems Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tactile Systems Technology and related companies with MarketBeat.com's FREE daily email newsletter.